Clinical Trials Logo

Radiofrequency Ablation clinical trials

View clinical trials related to Radiofrequency Ablation.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06033456 Recruiting - Mastectomy Clinical Trials

Combining Stellate Ganglion and T2 and T3 Radiofrequency Ablation on Post-mastectomy Complex Regional Pain Syndrome

Start date: October 7, 2023
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the efficacy of the combination of Ultra Sound (US) guided radiofrequency stellate ganglion block (SGB) and radiofrequency Thoracic Paravertebral block (TPVB) comparing to US-guided SGB or TPVB alone on the post-mastectomy pain syndrome (PMPS).

NCT ID: NCT06003218 Recruiting - Liver Cancer Clinical Trials

Dexmedetomidine-esketamine for Percutaneous Radiofrequency Liver Ablation

Start date: October 16, 2023
Phase: N/A
Study type: Interventional

Percutaneous radiofrequency ablation is a commonly treatment for patients with liver cancer that cannot be surgically resected. During the procedure, patients need to keep awake and cooperate with the procedure, including deep breath and hold breath. However, intolerable pain generated during puncture and radiofrequency heating may cause body movements and interfere the procedure. Oxycodone is frequently used for analgesia but still insufficient. A recent study showed that dexmedetomidine-esketamine combination improves analgesia without increasing adverse events. After stopping infusion, the analgesic/sleep-promoting effects of dexmedetomidine-esketamine seemed to last for up to 24 hours. The investigators hypothesize that dexmedetomidine-esketamine combination as a supplement to oxycodone will improve sedation and analgesia in patients undergoing radiofrequency liver ablation of the liver.

NCT ID: NCT05991856 Recruiting - Clinical trials for Radiofrequency Ablation

Multifaceted Comparison of Ultrasound-guided Ablation and Laparoscopic Adrenalectomy for Aldosterone-producing Adenoma

Start date: January 1, 2020
Phase:
Study type: Observational

The purpose of this study is to retrospectively and prospectively analyze the efficacy and safety of ultrasound-guided radiofrequency ablation and laparoscopic adrenalectomy in the treatment of aldosterone-producing adenoma (APA). It is planned to retrospectively collect 30 patients with adrenal radiofrequency ablation for APA and 15 patients with age - and sex-matched laparoscopic adrenalectomy for APA in our hospital from January 2020 to June 2024, and continue to follow up for 3 years.

NCT ID: NCT05916846 Recruiting - Pancreatic Cyst Clinical Trials

Endoscopic Ultrasound-guided Radiofrequency Ablation of Pancreatic Cysts (ERASE)

ERASE
Start date: April 24, 2023
Phase: N/A
Study type: Interventional

A single-center study to determine the safety and efficacy of EUS-guided radiofrequency ablation (RFA) of pancreatic cystic neoplasms (PCNs). Patients will be recruited sequentially to undergo RFA followed by standard surveillance. The study will recruit patients with pancreatic cystic lesions (PCLs) who are at high risk for surgical resection. Patients enrolled in the study will be followed up for 3-years after EUS-guided RFA.

NCT ID: NCT05818176 Recruiting - Clinical trials for Radiofrequency Ablation

To Improve the Clinical Outcome of Ultrasound-guided Radiofrequency Ablation by NAVIRFA® Navigation System.

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

Ultrasonic-guided radiofrequency ablation is the most common minimally invasive treatment for liver cancer. This study will use my country's self-developed intelligent ultrasonic navigation tool (NAVIRFA® Navigation System) to assist in the puncture of the needle during ablation, to observe the operation time, Whether the needle accuracy, ablation effect and complications are different from the traditional free-hand ultrasonic guidance technology.

NCT ID: NCT05500703 Recruiting - Epilepsy Clinical Trials

Brain Regions and Functional Neuronal Network Characteristics of Dexmedetomidine Analgesia

Start date: October 15, 2022
Phase: Phase 4
Study type: Interventional

Background: Dexmedetomidine (DEX) is a highly selective 2-adrenergic receptor agonist with significant analgesia affection. This study is planned to explore the brain regions and functional neuronal network involved in promoting analgesia of Dexmedetomidine. Methods: Select 12 patients with the proposed intraoperative MR-guided radiofrequency ablation of epilepsy. The subjects were randomized into the Dexmedetomidine group (DEX group) (n=6) and the Opioid group (OPI group) (n=6). DEX group: continuous intravenously administered 1.5 µg kg-1 h-1 dexmedetomidine 15min before anesthesia induction, continuous infusion for 15min after anesthesia induction, and then Intraoperative functional magnetic resonance imaging scanning was started. OPI group: the equivalent administered speed 0.9% sodium chloride was continuously pumped for 15min before anesthesia induction, then induce and intraoperative fMRI scanning started after continuous 30min infusion. The intraoperative fMIR scan results were compared and analyzed to find the unique analgesic brain regions of DEX, and the differences of the functional neuronal network of analgesia effect between the two groups.

NCT ID: NCT05142904 Recruiting - Clinical trials for Radiofrequency Ablation

Radiofrequency Ablation Versus I-131 for Solitary Autonomous Thyroid Nodules

RABITO
Start date: November 17, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare treatment of hyperthyroidism with radiofrequency ablation or I-131 for solitary autonomous thyroid nodules.

NCT ID: NCT04842253 Recruiting - Clinical trials for Radiofrequency Ablation

HFNC vs LFNC in Patients With AF Undergoing RFCA Under Deep Sedation.

Start date: January 4, 2022
Phase: N/A
Study type: Interventional

Oxygen supplementation through high flow nasal cannula (HFNC) may reduce the incidence of desaturation and hypoxemia during deep sedation at radiofrequency catheter ablation (RFCA procedures).This study is designed to test the hypothesis that the incidence of hypoxemia and desaturation in patients with atrial fibrillation undergoing RFCA under deep sedation, is less when using HFNC as compared to use of standard low flow nasal cannula (LFNC).

NCT ID: NCT04513119 Recruiting - Clinical trials for Radiofrequency Ablation

The Short-term Efficacy of Novel NTDP-RFA in the Treatment of Small HCC With Cirrhosis.

Start date: January 1, 2017
Phase:
Study type: Observational

To evaluate the short-term efficacy of novel no-touch combined directional perfusion radiofrequency ablation in the treatment of small hepatocellular carcinoma with cirrhosis.

NCT ID: NCT04471272 Recruiting - Clinical trials for Carcinoma, Hepatocellular

RFA Using Gradual RF Energy Delivery Mode With Octopus Electrodes

Start date: January 6, 2020
Phase: N/A
Study type: Interventional

The investigators intend to perform RFA therapy on HCC less than 4 cm in size using octopus electrode, double alternating unipolar high-frequency transmission mode and gradual high-frequency energy loading mode, and to find out the therapeutic results. The primary evaluation variable is the ideal technical success rate for securing a safety margin of 5 mm or more around the tumor on the CT obtained immediately after the procedure, and the secondary evaluation variable is the volume of the cauterization lesion per unit time measured on the CT obtained immediately after the procedure, The local tumor recurrence rate, survival rate and disease-free survival rate of 12 months after the procedure, the presence or absence of multiple recurrences within the same segment, the actual procedure time, and the incidence of complications associated with the procedure are examined. The performance of RFA therapy of HCC using the Octopus electrode and gradual high-frequency energy transfer mode is compared with that of the existing Octopus electrode and RFA therapy using the basic maximum high-frequency energy transfer mode using historic cohort.